Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib +/- Erlotinib in Advanced NSCLC Progressing on Erlotinib
NCT00609804Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2008
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Started Mar 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00609804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00609804.